Nuvalent, Inc.

Precision-oncology biotech developing brain-penetrant kinase inhibitors designed to address resistance and selectivity limitations.

Back to company catalog

Precision oncology / lung cancer · Targeted small-molecule kinase inhibitors · NDA under FDA review + Phase 3

Compare report options